Ahead of Organon (OGN) Q3 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Evaluate the expected performance of Organon (OGN) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Earnings Preview: Organon (OGN) Q3 Earnings Expected to Decline
Organon (OGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Organon (OGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Here's Why Organon (OGN) Gained But Lagged the Market Today
In the closing of the recent trading day, Organon (OGN) stood at $18.10, denoting a +0.56% change from the preceding trading day.
Organon (OGN) Loses -9.91% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Organon (OGN) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Organon (OGN) Stock Falls Amid Market Uptick: What Investors Need to Know
Organon (OGN) closed at $18.10 in the latest trading session, marking a -0.11% move from the prior day.
Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It
Organon (OGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Organon (OGN) Stock Dips While Market Gains: Key Facts
Organon (OGN) concluded the recent trading session at $18.58, signifying a -1.33% move from its prior day's close.
Why Organon (OGN) Outpaced the Stock Market Today
Organon (OGN) reachead $19.17 at the closing of the latest trading day, reflecting a +0.74% change compared to its last close.
Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know
Organon (OGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Roivant Flips a Skin Drug to Organon
Selling plaque psoriasis drug Vtama to Organon looks like another win for Roivant, which has been buying overlooked drugs, and then selling them for big returns.
Organon to buy therapy developer Dermavant for up to $1.2 billion
Healthcare company Organon said on Wednesday it has agreed to acquire Dermavant, a Roivant company, for up to $1.2 billion.
